The fallout from the COVID-19 pandemic has been challenging for many life sciences companies due to a wide range of factors. As a result, many companies around the world conducting clinical research have been forced to change trial protocols, delay trial recruitment and progress, and rethink timelines for regulatory submissions, approvals, and product launches.
We spoke with several industry insiders to better understand the longer term implications of COVID-19 for clinical research and how companies might be able to adapt and address potential risks to ensure their drug development efforts advance as rapidly as possible. While the impact of COVID-19 on clinical development programs is already severe, these stakeholders indicate that it is very likely that the effects will be both broad and long-lasting.
To access the article published in The Pharma Letter, click here.